Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Geron Corp GERN

Alternate Symbol(s):  GERNW

Healthcare Biotechnology
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the... see more

Recent & Breaking News (NDAQ:GERN)

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 19, 2022

Geron to Present at the H.C. Wainwright Global Investment Conference

Business Wire May 17, 2022

Geron Corporation Reports First Quarter 2022 Financial Results

Business Wire May 9, 2022

Geron to Announce First Quarter 2022 Financial Results on May 9, 2022

Business Wire May 2, 2022

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 21, 2022

Geron to Present at the 21st Annual Needham Virtual Healthcare Conference

Business Wire April 6, 2022

Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants

Business Wire April 1, 2022

Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants

Business Wire March 30, 2022

Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants

Business Wire March 29, 2022

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 17, 2022

Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones

Business Wire March 10, 2022

Geron to Announce Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Business Wire March 3, 2022

Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

Business Wire January 21, 2022

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 20, 2022

Geron to Present at the H.C. Wainwright BioConnect Conference

Business Wire January 4, 2022

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 16, 2021

Geron Reports Presentations at American Society of Hematology Annual Meeting

Business Wire December 14, 2021

Geron Announces Appointment of Chief Business Officer

Business Wire December 2, 2021

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 18, 2021

Geron to Present at the Stifel 2021 Virtual Healthcare Conference

Business Wire November 12, 2021